VIDEO: ‘Important’ positive, negative study results presented at SABCS
Click Here to Manage Email Alerts
In this video, Susan M. Domchek, MD, executive director of the Basser Center for BRCA and the director of the MacDonald Cancer Risk Evaluation Center at Penn Medicine, spoke with Healio about highlights from the San Antonia Breast Cancer Symposium.
One study, DESTINY-Breast03, which assessed trastuzumab deruxtecan (Enhertu; Daiichi Sankyo, AstraZeneca) was “a really important study and really a big change in things.”
She also discussed trials with negative results, including findings from studies assessing metformin and palbociclib (Ibrance, Pfizer) presented at the meeting.
Domchek stressed that “negative trials are also important, because we don’t want to subject our patients to things that don’t work.”
References:
Gnant M, et al. Abstract GS1-07. Presented at: San Antonio Breast Cancer Symposium; Dec. 7-10, 2021; San Antonio.
Goodwin PJ, et al. Abstract GS1-08. Presented at: San Antonio Breast Cancer Symposium; Dec. 7-10, 2021; San Antonio.
Hurvitz S, et al. Abstract GS3-01. Presented at: San Antonio Breast Cancer Symposium; Dec. 7-10, 2021; San Antonio.
Collapse
Read more about
Click Here to Manage Email Alerts